Cargando…

Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome

BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is characterized by excessive heart rate increase on standing and orthostatic intolerance. Previous data indicate autoimmune involvement. We studied serum activity against G protein–coupled receptors in relation to symptoms in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kharraziha, Isabella, Axelsson, Jonas, Ricci, Fabrizio, Di Martino, Giuseppe, Persson, Margaretha, Sutton, Richard, Fedorowski, Artur, Hamrefors, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792263/
https://www.ncbi.nlm.nih.gov/pubmed/32750291
http://dx.doi.org/10.1161/JAHA.120.015989
_version_ 1783633766939361280
author Kharraziha, Isabella
Axelsson, Jonas
Ricci, Fabrizio
Di Martino, Giuseppe
Persson, Margaretha
Sutton, Richard
Fedorowski, Artur
Hamrefors, Viktor
author_facet Kharraziha, Isabella
Axelsson, Jonas
Ricci, Fabrizio
Di Martino, Giuseppe
Persson, Margaretha
Sutton, Richard
Fedorowski, Artur
Hamrefors, Viktor
author_sort Kharraziha, Isabella
collection PubMed
description BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is characterized by excessive heart rate increase on standing and orthostatic intolerance. Previous data indicate autoimmune involvement. We studied serum activity against G protein–coupled receptors in relation to symptoms in patients with POTS and controls using a commercial cell‐based assay. METHODS AND RESULTS: Forty‐eight patients with POTS (aged 28.6±10.5 years; 44 women) and 25 healthy individuals (aged 30.7±8.6 years; 21 women) were included. The 10‐item Orthostatic Hypotension Questionnaire (OHQ) was completed by 33 patients with POTS and all controls. Human embryonic kidney 293 cells overexpressing one G protein–coupled receptor: adrenergic α(1) receptor, adrenergic β(2) receptor, cholinergic muscarinic type 2 receptor, and opioid receptor‐like 1 were treated with sera from all patients. Receptor response was analyzed using a β‐arrestin–linked transcription factor driving transgenic β‐lactamase transcription by fluorescence resonance energy transfer method. Receiver operating characteristic curves were constructed. G protein–coupled receptor activation was related to OHQ indices in linear regression models. Sera from patients with POTS activated all 4 receptors to a higher degree compared with controls (P<0.01 for all). The area under the curve was 0.88 (0.80–0.97, P<0.001) combining all 4 receptors. Adrenergic α(1) receptor activation associated with OHQ composite score (β=0.77 OHQ points per SD of activity, P=0.009) and with reduced tolerability for prolonged standing (P=0.037) and walking for short (P=0.042) or long (P=0.001) periods. All 4 receptors were associated with vision problems (P<0.05 for all). CONCLUSIONS: Our results indicate the presence of circulating proteins activating adrenergic, muscarinic, and nociceptin receptors in patients with POTS. Serum‐mediated activation of these receptors has high predictive value for POTS. Activation of adrenergic α(1) receptor is associated with orthostatic symptoms severity in patients with POTS.
format Online
Article
Text
id pubmed-7792263
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77922632021-01-15 Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome Kharraziha, Isabella Axelsson, Jonas Ricci, Fabrizio Di Martino, Giuseppe Persson, Margaretha Sutton, Richard Fedorowski, Artur Hamrefors, Viktor J Am Heart Assoc Original Research BACKGROUND: Postural orthostatic tachycardia syndrome (POTS) is characterized by excessive heart rate increase on standing and orthostatic intolerance. Previous data indicate autoimmune involvement. We studied serum activity against G protein–coupled receptors in relation to symptoms in patients with POTS and controls using a commercial cell‐based assay. METHODS AND RESULTS: Forty‐eight patients with POTS (aged 28.6±10.5 years; 44 women) and 25 healthy individuals (aged 30.7±8.6 years; 21 women) were included. The 10‐item Orthostatic Hypotension Questionnaire (OHQ) was completed by 33 patients with POTS and all controls. Human embryonic kidney 293 cells overexpressing one G protein–coupled receptor: adrenergic α(1) receptor, adrenergic β(2) receptor, cholinergic muscarinic type 2 receptor, and opioid receptor‐like 1 were treated with sera from all patients. Receptor response was analyzed using a β‐arrestin–linked transcription factor driving transgenic β‐lactamase transcription by fluorescence resonance energy transfer method. Receiver operating characteristic curves were constructed. G protein–coupled receptor activation was related to OHQ indices in linear regression models. Sera from patients with POTS activated all 4 receptors to a higher degree compared with controls (P<0.01 for all). The area under the curve was 0.88 (0.80–0.97, P<0.001) combining all 4 receptors. Adrenergic α(1) receptor activation associated with OHQ composite score (β=0.77 OHQ points per SD of activity, P=0.009) and with reduced tolerability for prolonged standing (P=0.037) and walking for short (P=0.042) or long (P=0.001) periods. All 4 receptors were associated with vision problems (P<0.05 for all). CONCLUSIONS: Our results indicate the presence of circulating proteins activating adrenergic, muscarinic, and nociceptin receptors in patients with POTS. Serum‐mediated activation of these receptors has high predictive value for POTS. Activation of adrenergic α(1) receptor is associated with orthostatic symptoms severity in patients with POTS. John Wiley and Sons Inc. 2020-07-30 /pmc/articles/PMC7792263/ /pubmed/32750291 http://dx.doi.org/10.1161/JAHA.120.015989 Text en © 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Kharraziha, Isabella
Axelsson, Jonas
Ricci, Fabrizio
Di Martino, Giuseppe
Persson, Margaretha
Sutton, Richard
Fedorowski, Artur
Hamrefors, Viktor
Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome
title Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome
title_full Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome
title_fullStr Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome
title_full_unstemmed Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome
title_short Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome
title_sort serum activity against g protein–coupled receptors and severity of orthostatic symptoms in postural orthostatic tachycardia syndrome
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792263/
https://www.ncbi.nlm.nih.gov/pubmed/32750291
http://dx.doi.org/10.1161/JAHA.120.015989
work_keys_str_mv AT kharrazihaisabella serumactivityagainstgproteincoupledreceptorsandseverityoforthostaticsymptomsinposturalorthostatictachycardiasyndrome
AT axelssonjonas serumactivityagainstgproteincoupledreceptorsandseverityoforthostaticsymptomsinposturalorthostatictachycardiasyndrome
AT riccifabrizio serumactivityagainstgproteincoupledreceptorsandseverityoforthostaticsymptomsinposturalorthostatictachycardiasyndrome
AT dimartinogiuseppe serumactivityagainstgproteincoupledreceptorsandseverityoforthostaticsymptomsinposturalorthostatictachycardiasyndrome
AT perssonmargaretha serumactivityagainstgproteincoupledreceptorsandseverityoforthostaticsymptomsinposturalorthostatictachycardiasyndrome
AT suttonrichard serumactivityagainstgproteincoupledreceptorsandseverityoforthostaticsymptomsinposturalorthostatictachycardiasyndrome
AT fedorowskiartur serumactivityagainstgproteincoupledreceptorsandseverityoforthostaticsymptomsinposturalorthostatictachycardiasyndrome
AT hamreforsviktor serumactivityagainstgproteincoupledreceptorsandseverityoforthostaticsymptomsinposturalorthostatictachycardiasyndrome